Phase I and pharmacologic study of oral (E)-2'-deoxy-2'-(fluoromethylene) cytidine: On a daily x 5-day schedule

Investigational New Drugs

Volumn 16, Issue 3, 1998, Pages 245-254

  Masuda, Noriyuki ^a   Negoro, Shunichi ^b   Takeda, Kouji ^b   Takifuji, Nobuhide ^b   Hirashima, Tomonori ^b   Yana, Takashi ^a   Kurata, Noriaki ^c   Kuwabara, Takashi ^c   Kobayashi, Satoshi ^c   Kudoh, Shinzoh ^a   Matsui, Kaoru ^a   Takada, Minoru ^a   Fukuoka, Masahiro ^d  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Deoxycytidine analog; FMdC; Phase I trial; Ribonucleoside diphosphate reductase inhibitor

Indexed keywords

TEZACITABINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TOXICITY; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HERPES; HUMAN; HYPOTENSION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; MEAN RESIDENCE TIME; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE;

EID: 6544291123     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006126212481     Document Type: Article

References (22)

1. Elford H, Freese M, Passamani E, Morris H: Ribonucleotide reductase and cell proliferation. J Biol Chem 245: 5228-5233, 1970
2. McCarthy JR, Matthews DP, Stemerick DM, Huber EW, Bey P, Lippert BJ, Snyder RD, Sunkara PS: Stereospecific method to E and Z terminal fluoro olefins and its application to the synthesis of 2′-deoxy-2′-fluoromethylene nucleosides as potential inhibitors of ribonucleoside diphosphate reductase. J Am Chem Soc 113: 7439-7440, 1991
3. Yonetani Y, Mizukami T: Kinetic analysis of inhibition of human ribonucleotide reductase and DNA polymerase a by a new anticancer agent, (E)-2′-deoxy-2′-(fluoromethylene)cytidine. Proc Am Assoc Cancer Res 37: 405, 1996
4. Kyowa-Hakko Kogyo Co. L: Investigators Brochure of KW-2331 (in Japanese) Kyowa Hakko Kogyo, Co., Ltd. Tokyo, Japan, 1994
5. Kanazawa J, Takahashi T, Gomi K, Okabe M: Antitumor activity of (E)-2′-deoxy-2′-(fluoromethylene)cytidine, an inhibitor of ribonucleotide reductase. Proc Am Assoc Cancer Res 36: 405, 1995
6. Sunkara PS, Zwolshen JH, Lippert BJ, Snyder RD, Matthews D, McCarthy JR: Antitumor activity of (E)-2′-fluoromethylene-2′-deoxycytidine (FMdC, MDL 101,731): a novel inhibitor of ribonucleotide reductase specific drags. Proc Am Assoc Cancer Res 32: 415, 1991
7. Bitonti AJ, Dumont JA, Bush TL, Cashman EA, Cross-Doersen DE, Wright PS, Matthews DP, McCarthy JR, Kaplan DA: Regression of human breast tumor xenografts in response to (E)-2′-deoxy-2′-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase. Cancer Res 54: 1485-1490, 1994
8. Bitonti AJ, Bush TL, Lewis MT, Sunkara PS: Response of human colon and prostate tumor xenografts to (E)-2′-deoxy-2′-(fluoromethylene)cytidine, an inhibitor of ribonucleotide reductase. Anticancer Res 15: 1179-1182, 1995
9. Piepmeier JM, Rabidou N, Schold SC, Bitonti AJ, Prakash NJ, Bush TL: In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor. Cancer Res 56: 359-361, 1996
10. Wright PS, Cross Doersen D, Th'ng JPH, Guo XW, Crissman HA, Bradbury EM, Montogomery LR, Thompson FY, Loudy DE, Johnston JO, Bitonti AJ: A ribonucleotide reductase inhibitor, MDL-101,731, induced apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts. Exp Cell Res 222: 54-60, 1996
11. Mountain CF: A new international staging system for lung cancer. Chest 89: 225S-233S, 1996
12. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48, Geneva, Switzerland, World Health Organization, 1979
13. Ho DH-W: Distribution of kinase and deaminase of 1-b-D-arabinofuranosylcytosine of tissues of man and mouse. Cancer Res 33: 2816-2820, 1973
14. Sunderman, FW: The clinical biochemistry of 5′-nucleotidase. Ann Clin Lab Sci 20: 123-139, 1990
15. Gibaldi M, Perrier D: Pharmacokinetics. 2nd ed, Marcel Dekker, New York, 1982, pp 85-111, pp 409-417
16. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T: A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4: 879-885, 1981
17. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491-498, 1991
18. Poplin EA, Corbett T, Flaherty L, Tarasoff P, Redman BG, Valdivieso M, Baker L: Difluorodeoxycytidine (dFdC) - gemcitabine: a phase I study. Invest New Drugs 10: 165-170, 1992
19. O'Rourke TJ, Brown TD, Havlin K, Kuhn JG, Craig JB, Burris HA, Satterlee PG, Tarassoff PG, Von Hoff DD: Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer 30A: 417-418, 1994
20. Anderson H, Thatcher N, Walling J, Hansen H: A phase I study of a 24-hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer 74: 460-462, 1996
21. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA: Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 12: 1535-1540, 1994
22. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH: Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 12: 1821-1826, 1994